Skip to main content
Equibles
VSTM logo

VSTM · Verastem, Inc. · Metrics

Track VSTM — free

Use VSTM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VSTM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.04 -0.02 (-0.20%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“However, given the risks associated with these potential strategic or financing opportunities, they are not deemed probable for purposes of the going concern assessment and do not alleviate the substantial doubt about our ability to continue as a going concern. There can be no assurance that we will be able to generate sufficient net product revenues or obtain additional capital on favorable terms or at all.”
View the 10-Q filed Aug 6, 2026
Market Cap
$909.26M
Shares
90.56M
Volume · Oct 23 3.76M Avg daily vol (3M) 3.18M

VSTM metrics

72 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$10.04
Market cap
$909.26M

Price action

20 metrics
Price change (1W)
+16.1%
Price change (30D)
+28.7%
Price change (3M)
+66.0%
Price change (6M)
+69.9%
Price change (YTD)
+30.1%
Price change (1Y)
+28.6%
Trailing year
Price change (5Y)
—
52-week high
$10.64
52-week low
$3.45
Change from 52-week high
-5.6%
Change from 52-week low
+191.0%
Annualized volatility
76.6%
Annualized volatility (3M)
75.5%
Beta
1.3
RSI (14D)
67.2
Price vs SMA 50
+27.5%
Price vs SMA 200
+64.4%
Avg volume (3M)
3.18M
Relative volume
1.2
Average dollar volume
$24.92M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
90.56M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
10.2×
reciprocal yield 9.9%
P / book
17.8
reciprocal yield 5.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-22.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
54.2×
reciprocal yield 1.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-14

Profitability

9 metrics
Gross margin
—
Operating margin
-550.3%
Trailing 12 months
Net margin
-677.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$159.80M
Net income (TTM)
−$202.70M
Trailing 12 months
Diluted EPS (TTM)
$-2.25
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.88
EBITDA per diluted share (TTM)
$-11.79
Net income per diluted share (TTM)
$-2.50
Operating cash flow per diluted share (TTM)
$-1.86
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$1.61
Stock compensation per diluted share (TTM)
$0.11
Book value per share
$0.74

Growth

11 metrics
Revenue growth YoY
+1,775.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$87.53M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+35.2%
Year over year · more shares
Revenue CAGR (3Y)
+128.4%
Revenue CAGR (5Y)
-19.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-405.5%
Return on assets
-98.2%
Debt / equity
—
Current ratio
2.3
EBITDA (TTM)
−$36.33M
Free cash flow (TTM)
—
Quick ratio
2.2
Interest coverage
-108.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$136.35M
Total assets
$206.51M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$162.19M
Capital expenditures (TTM)
$28,000
R&D (TTM)
$140.22M
SG&A (TTM)
$95.16M
Stock compensation (TTM)
$9.68M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
159
13F filer change QoQ
+2
Institutional ownership
105.8%
Conviction holders (share of 13F filers)
1.3%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+13.4%
Holder tenure
8.0
Price vs estimated holder cost
-40.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
15.5%

Short interest

3 metrics
Short interest
16.5%
Latest settlement · 7.0 days to cover
Days to cover
7.0d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$381,484
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1526119 CUSIP 92337C203 13F (30d) 18 filings 18 filers Visit website Investor relations